Immunitybio Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Immunitybio Inc 's ROA in the second quarter of 2026?
Immunitybio Inc recorded a cumulative net loss of $-992 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -172.99%.

However, within the Healthcare sector 831 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4428, from total ROA ranking in the first quarter of 2026 at 4882.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	56 %	112.88 %	43.15 %	56.83 %	-2.61 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-992	-855	-351	-349	-367
Return On Assets (TTM)	-172.99 %	-165.17 %	-81.42 %	-88.53 %	-105.86 %
IBRX's Total Ranking	# 4428	# 4882	# 4335	# 4457	# 4559
Total Assets (TTM) in million	627	647	502	519	402
Seq. Total Assets Change	-3 %	28.84 %	-3.29 %	29.08 %	32.37 %
Seq. Net Income Change	-	-	-	-	-

IBRX's 5 Years Annual ROA >> Back to IBRX Management Effectiveness >> Compare IBRX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 129
Sector	# 832
Overall	# 4399

Return On Assets Statistics
High	Average	Low
-32.05 %	-89.19 %	-172.89 %
(Sep 30 2017)		(Jun 30 2026)

News about Immunitybio inc Return on Assets ROA

ImmunityBio Unveils Promising Long-Term NSCLC Survival Data, Plans Phase 3 Trials with ANKTIVA and Checkpoint Immun...

Culver City, Calif. ImmunityBio, Inc. (NASDAQ: IBRX), a pioneering force in immunotherapy, has announced promising results from its QUILT 3.055 trial demonstrating robust long-term survival benefits for patients suffering from advanced non-small cell lung cancer (NSCLC). These findings were presented by John Wrangle, M.D. MPH, Associate Professor at the Medical University of South Carolina, during an oral presentation at the prestigious World Conference on Lung Cancer.The recent data highlights a significant breakthrough, revealing a long-term extended survival period ranging from 14 months to as much as five years for NSCLC patients treated with the combination of ANKTIVA and checkpoint inhibitors (CPI). This milestone revelation signifies a considerable leap forward in the treatment of advanced NSCLC and offers hope to thousands battling this aggressive disease.

Financial Statements
Immunitybio Inc 's Assets	$ 627 million	IBRX's Balance sheet
Immunitybio Inc 's Income	$ -230 million	Quarterly IBRX's Income Statement
IBRX's Income by Division		See IBRX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	43.15 %	-25.27 %	47.03 %	-26.56 %	228.07 %
Total Assets in million	502	351	469	319	434
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-351	-414	-584	-417	-350
Annual Return On Assets	-70.03 %	-117.98 %	-124.45 %	-130.79 %	-80.53 %

IBRX's 5 Years Annual ROA >> Back to IBRX Management Effectiveness >> Compare IBRX ROA to its Competitors

More Return On Assets Ratios
IBRX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IBRX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IBRX's Competitors
Subscribers only: Roa for Immunitybio Inc 's Suppliers
Subscribers only: Return On Assets for IBRX's Customers

You may also want to know
IBRX's Roi	IBRX's Inventory Turnover Ratio	IBRX's Growth Rates	IBRX's Dividend Comparisons
	IBRX's Profitability Ratios	IBRX's Asset Turnover Ratio	IBRX's Dividend Growth
IBRX's Roe	IBRX's Valuation Ratios	IBRX's Financial Strength Ratios	IBRX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-30T21:40:58+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.